


=> d l2; d his; log y
 L2 HAS NO ANSWERS
 L1 STR



G2
 G1 O,S,N
 G2 [@1],[@2],[@3],[@4],[@5],[@6]

Structure attributes must be viewed using STN Express query preparation.
 L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 16:43:14 ON 09 MAR 2006)

FILE 'REGISTRY' ENTERED AT 16:43:27 ON 09 MAR 2006

L1 STRUCTURE UPLOADED
 L2 QUE L1
 L3 0 S L2
 L4 3 S L2 FUL

FILE 'CAPLUS' ENTERED AT 16:44:12 ON 09 MAR 2006


L5 1 S L4

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	5.57	172.72
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.75	-0.75

STN INTERNATIONAL LOGOFF AT 16:45:04 ON 09 MAR 2006

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2001:115130 CAPLUS Full-text
 DN 134:178474
 TI Preparation of oxobenzazepinealkanoates and analogs as integrin receptor antagonists
 IN Kling, Andreas; Geneste, Herve; Lange, Udo; Lauterbach, Arnulf; Graef, Claudia Isabella; Subkowski, Thomas; Holzenkamp, Uta; Mack, Helmut; Sadowski, Jens; Hornberger, Wilfried; Laux, Volker
 PA BASF Aktiengesellschaft, Germany
 SO PCT Int. Appl., 158 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001010847	A2	20010215	WO 2000-EP7440	20000801
	WO 2001010847	A3	20011101		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG DE 19936780 A1 20010215 DE 1999-19936780 19990809 CA 2379977 AA 20010215 CA 2000-2379977 20000801 EP 1202988 A2 20020508 EP 2000-958347 20000801 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL BR 2000013265 A 20020514 BR 2000-13265 20000801 TR 200200357 T2 20020923 TR 2002-200200357 20000801 JP 2003506441 T2 20030218 JP 2001-515313 20000801 BG 106395 A 20021229 BG 2002-106395 20020206 NO 2002000644 A 20020318 NO 2002-644 20020208 PRAI DE 1999-19936780 A 19990809 WO 2000-EP7440 W 20000801 OS MARPAT 134:178474 GI				




AB RZZ1R1 [I; R = group contg, ≥ 1 non-H H-bonding atom; R1 = CO2H, or group hydrolyzable to CO2H; Z = e.g., (hetero)annelated 2-oxo-1-benzazepin-1,5-diyl; Z1 = bond, (un)substituted NHCH2, -OCH2, -alkylene, -CH:CH, etc.] were prepared. Thus, Me 11-methoxycarbonylmethyl-6-oxo-6,11-dihydro-5H-dibenz[b,e]azepine-5-acetate (preparation given) was amidated by N-(2-aminoethyl)pyridine-2-amine to give, after saponification, title compound II. Data for biol. activity of I were given.
 IT 326402-02-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxobenzazepinealkanoates and analogs as integrin receptor antagonists)

RN 326402-02-2 CAPLUS

CN 5H-Dibenz[b,e]azepine-5-acetic acid, 11-[2-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



IT 326408-68-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of oxobenzazepinealkanoates and analogs as integrin receptor antagonists)

RN 326408-68-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-5-acetic acid, 11-[2-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

